Chemical Property of Omarigliptin (MK-3102)
Chemical Property:
- Boiling Point:529.4±60.0 °C(Predicted)
- PKA:9.11±0.60(Predicted)
- PSA:98.83000
- Density:1.61±0.1 g/cm3(Predicted)
- LogP:2.86110
- Storage Temp.:2-8°C(protect from light)
- Solubility.:insoluble in EtOH; insoluble in H2O; ≥17.15 mg/mL in DMSO
- Purity/Quality:
-
99%, *data from raw suppliers
Omarigliptin *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
-
Description
Merck earned its first global
approval for omarigliptin in Japan in 2015, and phase III
development is ongoing in other countries around the globe for
this interesting small molecule DPP-4 inhibitor. Interestingly,
while most DPP-4 inhibitors used to treat type 2 DM require
daily administration, omarigliptin is a weekly treatment. The
process-scale synthesis of omarigliptin has been nicely
described in an October 2015 paper from the Merck process
group. MK-3102 is a potent, reversible, and competitive inhibitor of dipeptidyl peptidase 4 (DPP-4; IC50 = 1.6 nM; Ki = 0.8 nM). It is selective for DPP-4 over 168 proteases, ion channels, and enzymes with IC50 values greater than 10 μM in all assays. MK-3102 significantly reduces blood glucose levels in a dose-dependent manner in vivo in rats. It also has a long half-life (11 and 22 hours in rat and dog, respectively) making it suitable for once weekly dosing. Clinical trials demonstrate that formulations containing MK-3102 reduce plasma glucose and HbA1c in patients with type 2 diabetes mellitus (T2DM).
-
Uses
Omarigliptin is a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor to be used as treatment for type 2 diabetes.